MedComm – Biomaterials and Applications最新文献

{"title":"Preparation and intraocular evaluation of cetirizine hydrochloride ophthalmic liposomes and a liposome in situ gel","authors":"Jing Zhang,&nbsp;Lan Wang,&nbsp;Jianghong Li,&nbsp;Yuhong Guo,&nbsp;Jinxin Chen,&nbsp;Xudong Li,&nbsp;Man Cheng,&nbsp;Bo Feng,&nbsp;Ying Zhang","doi":"10.1002/mba2.39","DOIUrl":"https://doi.org/10.1002/mba2.39","url":null,"abstract":"<p>Cetirizine hydrochloride (CTZ), an antiallergic drug, is a new-generation H1 receptor antagonist and a second-generation H1 antihistamine. We aimed to prepare cetirizine hydrochloride liposomes, based on which cetirizine hydrochloride liposomal (CTZL) in situ gel (ISG) was prepared, to improve the retention time in the eye. CTZL were prepared by the ethanol injection method combined with the ammonium sulfate gradient method. A CTZ liposomal temperature-sensitive gel was prepared using the cold dissolution method. Large-eared white rabbits were used in retention and irritation experiments. The liposomes were small single-chambered liposomes, spherical or sphere-like, with a vesicle size of 187.03 ± 6.20 nm, an encapsulation efficiency of 70.39 ± 1.13%, and a drug loading capacity of 4.63 ± 0.06%. The gelling temperatures before and after dilution by simulated tear fluid were 26.1 ± 0.2°C and 34.2 ± 0.2°C, the vesicle size was 184.94 ± 7.28 nm, and the liposomes were spherical or sphere-like in the gel matrix. The in vitro dissolution and release experiments indicate that the gel was released upon dissolution and exhibited a zero-level release pattern. Preparation into liposomes and liposomal gels prolonged the ocular retention time of the formulation without ocular irritation.</p>","PeriodicalId":100901,"journal":{"name":"MedComm – Biomaterials and Applications","volume":"2 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mba2.39","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50137455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanotechnology connecting copper metabolism and tumor therapy","authors":"Yongjuan Li,&nbsp;Ya Dong,&nbsp;Xinyao Zhou,&nbsp;Kelong Fan","doi":"10.1002/mba2.36","DOIUrl":"https://doi.org/10.1002/mba2.36","url":null,"abstract":"<p>Copper (Cu) is an essential trace element in the human body that is involved in the formation of several natural enzymes, such as superoxide dismutase and cyclooxygenase. Due to the high density of the outer electron cloud of Cu, which allows the transfer of multiple electrons, Cu is often used as the catalytic center in various metabolic enzymes. However, both deficiency and excessive accumulation of Cu can result in irreversible damage to cells. Therefore, strategies to regulate Cu metabolism, such as Cu exhaustion and Cu supplementation, have emerged as attractive approaches in anticancer therapy, due to the potential damages caused by Cu metabolism disorders. Notably, recent advancements in nanotechnology have enabled the development of nanomaterials that can regulate Cu metabolism, making this therapy applicable in vivo. In this review, we provide a systematic discussion of the physical and chemical properties of Cu and summarize the applications of nanotechnology in Cu metabolism-based antitumor therapy. Finally, we outline the future directions and challenges of nano-Cu therapy, emphasizing the scientific problems and technical bottlenecks that need to be addressed for successful clinical translation.</p>","PeriodicalId":100901,"journal":{"name":"MedComm – Biomaterials and Applications","volume":"2 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mba2.36","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50132089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent progress in orodispersible films-mediated therapeutic applications: A review","authors":"Yu Tian,&nbsp;Jiangtao Lin,&nbsp;Hongshu Jing,&nbsp;Quan Wang,&nbsp;Zhihua Wu,&nbsp;Yourong Duan","doi":"10.1002/mba2.34","DOIUrl":"https://doi.org/10.1002/mba2.34","url":null,"abstract":"<p>Orodispersible films (ODFs) as a relatively novel delivery platform have increasingly attracted enormous attention owing to their various advantages compared to conventional oral dosage forms, including fast disintegration, ease of administration without consumption of water, and rapid absorption of incorporated drug, high patient compliance for pediatrics, geriatrics and patients with swallowing difficulties. This review aims to summarize the developments and possibilities that ODFs as the potential carrier for chemical drugs, vaccine, probiotics, and herbal extracts. Especially, with the outbreak of coronavirus disease 2019 (COVID-19), the advantages of ODFs related to ease of transporation and distribution without cold-chain as well as low-cost manufacturing make ODFs a promising carrier for vaccines against COVID-19. Subsequently, the current therapeutic applications of ODFs delivered either locally or systemically for potential patients suffering from various diseases are discussed, including oral inflammation, cardiovascular diseases, pain disorders, nausea and vomiting, mood or mental disorders, erectile dysfunction and pulmonary diseases. Finally, this review provides overview of the novel inkjet printing and three-dimensional printing techniques, and the possibility of extemporaneous preparation for ODFs in hospital pharmacies via printing techniques are discussed as well.</p>","PeriodicalId":100901,"journal":{"name":"MedComm – Biomaterials and Applications","volume":"2 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mba2.34","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50126374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colorimetric detection of SARS-CoV-2 variants with paper-based analytical devices","authors":"Qi Wang,&nbsp;Zhaowei Chen,&nbsp;Huanghao Yang","doi":"10.1002/mba2.35","DOIUrl":"https://doi.org/10.1002/mba2.35","url":null,"abstract":"<p>Given that the severe acute respiratory syndrome coronavirus 2 (SRAS-CoV-2) virus keeps mutating during the COVID-19 pandemic, there is an urgent need to develop a quick and convenient test method to detect real-life samples for mass on-site screening. Zhang et al. proposed a novel strategy for rapid detection and discrimination of SARS-CoV-2 and its variants at rather low cost utilizing a subtly designed DNA probe. By combining with a paper-based colorimetric amplification platform, the results could be analyzed by the naked eyes or a widely used smartphone.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":100901,"journal":{"name":"MedComm – Biomaterials and Applications","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mba2.35","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50137199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanobiotechnology-mediated radioimmunotherapy treatment for triple-negative breast cancer","authors":"Mei Zhu,&nbsp;Xi Yang,&nbsp;Jia You,&nbsp;Lingnan Zheng,&nbsp;Cheng Yi,&nbsp;Ying Huang","doi":"10.1002/mba2.32","DOIUrl":"https://doi.org/10.1002/mba2.32","url":null,"abstract":"<p>Breast cancer has become the most common and greatest threat to women's health in the world. As the most dangerous subtype of breast cancer, triple-negative breast cancer (TNBC) can lead develop drug resistance, resulting in poor therapeutic effects. The synergistic effect of radiotherapy and immunotherapy can not only improve the therapeutic effect of in situ TNBC but also induce the strong abscopal effect of radiotherapy to remove the tumor cells from the metastatic tumor and prevent tumor recurrence. However, many preclinical studies have pointed out that the application of radioimmunotherapy still has such problems as large toxic and side effects of drugs and asynchronous administration scheme. With the increasing popularity of nanobiotechnology in tumor therapy, there are more and more research results related to nanoparticles, such as inorganic nanoparticles, organic nanoparticles, and nanoparticle–hydrogel complexes in radioimmunotherapy. In this review, we briefly summarize the related clinical treatment methods of TNBC and review the related nanobiotechnology used in the preclinical studies of TNBC radioimmunotherapy. It is mainly characterized by the controlled release of drugs locally, enhanced radiosensitization, and avoidance of systemic toxicity. However, further studies are needed to improve the convenience and effectiveness, so as to explore new options for the clinical treatment of TNBC.</p>","PeriodicalId":100901,"journal":{"name":"MedComm – Biomaterials and Applications","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mba2.32","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50150818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomimetic photosynthetic system: Shedding light on the restoration of cell metabolism","authors":"Jiayi Hu,&nbsp;Fangman Chen,&nbsp;Dan Shao","doi":"10.1002/mba2.33","DOIUrl":"https://doi.org/10.1002/mba2.33","url":null,"abstract":"<p>Specific mature cell membrane camouflaging facilitated the internalization of nanothylakoids through homologous targeting and membrane fusion. Under red light irradiation, the biomimetic nanothylakoids (cell membrane-camouflaged nanoparticulate thylakoids, CM-NTUs) would provide sufficient ATP and increase nicotinamide adenine dinucleotide phosphate (NADPH) to correct energy imbalance to improve metabolic homeostasis through enhancing anabolism in degenerated cells. Consequently, CM-NTUs promoted cartilage homeostasis and remarkedly ameliorated osteoarthritis progression in animals, offering therapeutic avenues for various degenerative diseases.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":100901,"journal":{"name":"MedComm – Biomaterials and Applications","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mba2.33","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50120387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dendrimer and dendrimer gel-derived drug delivery systems: Breaking bottlenecks of topical administration of glaucoma medications","authors":"Juan Wang,&nbsp;Boxuan Li,&nbsp;Uday B. Kompella,&nbsp;Hu Yang","doi":"10.1002/mba2.30","DOIUrl":"https://doi.org/10.1002/mba2.30","url":null,"abstract":"<p>Due to high structural flexibility, multidrug carrying capability, and tunable size, dendrimers have been used as suitable carriers for ophthalmic drug delivery. Drug molecules can be either encapsulated or chemically coupled to dendrimers. The nanoscopic size, spheroidal shape, and cationic surface of polyamidoamine (PAMAM) dendrimers promote their interaction with the cornea and result in prolonged precorneal retention. Dendrimers could be further cross-linked to produce three-dimensional hydrogel networks or dendrimer hydrogels (DH). The properties of the DH can be readily adjusted to maintain both fluidity and adhesiveness, making them suitable for developing topical ocular drug formulations. Micro-/nano- sized DHs, that is, dendrimer micro-/nano- gels, have unique properties such as ease of administration, large specific surface area for adhesion, and drug targeting functionalities, making them attractive for ophthalmic drug delivery. This perspective reports advances in PAMAM dendrimer based drug delivery systems including drug conjugates and micro- and nano- gels to enhance and sustain the delivery of multiple anti-glaucoma drugs, Dendrimer and dendrimer gel-derived drug delivery systems hold great potential as multifunctional  topical drug delivery systems for the eye.</p>","PeriodicalId":100901,"journal":{"name":"MedComm – Biomaterials and Applications","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mba2.30","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50138568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amphiphilic photosensitizer polymer as a nanocarrier of cytotoxic molecule for carrier-free combination therapy","authors":"Jingqi Xin,&nbsp;Caiting Deng,&nbsp;Meichen Zheng,&nbsp;Feifei An","doi":"10.1002/mba2.28","DOIUrl":"https://doi.org/10.1002/mba2.28","url":null,"abstract":"<p>Various nanocarriers have been explored to deliver drugs for combination therapy. However, most nanocarriers are composed of inert materials without contribution for improving the cancer therapeutic effect. Herein, a hydrophobic photosensitizer is conjugated to poly (ethylene glycol) to form an amphiphilic polymer, which further self-assembles into nanomicelle. The generated nanomicelle can act as a nanocarrier to encapsulate a cytotoxic molecule, IR-775, for combination therapy. The yielded nanodrug is totally composed of pharmacologically active ingredients to avoid any possible toxicity resulted from carrier materials. The nanodrug performs enhanced therapeutic effect compared with any monotherapy and exhibits negligible hemolysis, indicating good biocompatibility for further in vivo applications.</p>","PeriodicalId":100901,"journal":{"name":"MedComm – Biomaterials and Applications","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mba2.28","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50126151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting staphylococcal bone infections","authors":"Zhang Xiangchun,&nbsp;Xulin Hu,&nbsp;Hongping Chen","doi":"10.1002/mba2.31","DOIUrl":"https://doi.org/10.1002/mba2.31","url":null,"abstract":"<p>A novel quinolone antibiotic was developed by Shiladitya Sengupta and colleagues using molecular-docking simulation, and one lead compound, VCD-077, was selected based on this strategy.<span>¹</span> Antimicrobial resistance is increasing, driven by widespread antibiotic overuse in medical and agricultural settings.<span>²</span> Paradoxically, despite the urgent need to develop a new generation of antibiotics, their marketability is suppressed, partly because the new antibacterial drug may quickly develop new resistance and the development of new antibiotics is sluggish.<span>^{3, 4}</span> The ideal next-generation antibiotic should demonstrate excellent activity against drug-resistant bacteria, good biosafety, flexible drug delivery, and the ability to retard the development of resistance. In this regard, recently researchers have focused on developing novel antibiotics by improving drug performance, availability, targeted enrichment, and reducing systemic toxicity.</p><p>Reporting in Nature Biomedical Engineering, Shiladitya Sengupta and colleagues now show that VCD-077 screened by molecular-docking simulations exhibits excellent activity against drug-resistant bacteria and its biofilms, reduces the development of bacterial resistance and is compatible with bone cement for local delivery and treatment of staphylococcal bone infections in rats (Figure 1).<span>¹</span></p><p>Bone infections are rising rapidly due to accidental fractures and the global aging population.<span>⁵</span> Sengupta and co-authors designed a series of quinolone antibiotics using molecular-docking simulation. They selected VCD-077 from 17 candidate antibiotics, which can effectively against clinical drug-resistant staphylococcal and retard the development of resistance. The minimal inhibitory concentration (MIC) of ciprofloxacin, <i>Staphylococcus aureus</i> sensitive antibiotics, increased stepwise to 64.0 μg/ml by the 20th passage to <i>S. aureus</i>. While <i>S. aureus</i> were still sensitive to VCD-077 even at the 28th passage. Specifically, VCD-077 is potent against <i>S. aureus</i> and <i>Staphylococcus epidermidis</i> biofilms because it is a weak acid with a single pKa of 5.8, that is, it still maintains antibacterial activity at pH 5.5–7.4. In contrast, gentamicin lost part of its activity at acid pH 5.5. Therefore, VCD-077 has a unique advantage in the prevailing weakly acidic infected bone environment. Notably, VCD-077 is physicochemically compatible with polymethylmethacrylate bone cement, exhibits desired pharmacokinetics without loss of mechanical properties of bone cement. VCD-077-impregnated bone cement showed more powerful anti-infective activity compared with either FDA-approved rifampin or gentamicin-impregnated bone cement. Overall, the authors show that VCD-077-impregnated bone cement could be used as rational next-generation drugs or coatings to treat bone infections.</p><p>The high efficacy ","PeriodicalId":100901,"journal":{"name":"MedComm – Biomaterials and Applications","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mba2.31","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50121311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2-Hydroxy-1,4-naphthoquinone [Lawsone] integrated rare-earth hybrid materials as biocompatible UV/IR filter agents","authors":"Sheemol V. Narayanan,&nbsp;Muthusundar Kumar,&nbsp;Valan R. Gnanaraj,&nbsp;Sruthi C. Rajan,&nbsp;Viji Selvaraj,&nbsp;Solaiappan Ananthakumar","doi":"10.1002/mba2.29","DOIUrl":"https://doi.org/10.1002/mba2.29","url":null,"abstract":"<p>UV filter agents are essential ingredients in cosmetics and fabrics for rendering the property of protection from harmful UV radiation. The focus of this research was on the development of biocompatible hybrid UV/IR filter agents through sol–gel processing of nano-sized lanthanum titanate, zirconate, and phosphate-based rare-earth materials. 2-Hydroxy-1,4-naphthoquinone (Lawsone) is an ideal candidate, owing to its biocompatibility, for treating the sol of the rare-earth systems to produce inorganic-organic hybrids with classical orange shades. The rare-earth hybrids were characterized by X-Ray diffraction, dynamic light scattering, fourier transform infrared spectroscopy, scanning electron microscopy, UV-Vis, photo-luminescence, and Near Infrared (NIR) spectroscopy. The results of characterization indicated that the hybrids offer &gt;90% of NIR reflectance in the wavelength region from 700 to 1100 nm. They also exhibited excellent shielding in UV-A and UV-B regions, thus qualifying them as cool colors with useful optical as well as heat management characteristics. The sun protection factor calculated by optical density measurements showed that the synthesized hybrids have potential applications as UV filter agents in sunscreen lotions. The cell viability analyzed by the MTT (4,5-dimethylthiazol-2-yl)−2,5-diphenyltetrazolium bromide) assay affirmed the biocompatibility of the hybrids as none of the systems was found cytotoxic. This study was devoted to exploring the beneficial properties of rare-earth-based hybrid systems in pharmacological applications.</p>","PeriodicalId":100901,"journal":{"name":"MedComm – Biomaterials and Applications","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mba2.29","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50145418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}